Edoardo Biancalana Giovanni Ceccarini Silvia Magno Valerio Ortenzi Domenico Giannese Ferruccio Santini Anna Solini
10.3389/fendo.2023.1172468
Front Endocrinol (Lausanne)
2023 May 19;14:1172468.
canagliflozin case report dual renin-angiotensin system blockade lipodystrophy metreleptin proteinuria
CC BY
https://pubmed.ncbi.nlm.nih.gov/37274321/
Diabetes Mellitus, Type 2 / complications Diabetes Mellitus, Type 2 / drug therapy Lipodystrophy / drug therapy Renal Insufficiency, Chronic / complications Renal Insufficiency, Chronic / drug therapy Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
Diabetes Mellitus, Type 2 / complications Diabetes Mellitus, Type 2 / drug therapy Lipodystrophy / drug therapy Renal Insufficiency, Chronic / complications Renal Insufficiency, Chronic / drug therapy Sodium-Glucose Transporter 2 Inhibitors / therapeutic use Case Reports Adult Canagliflozin / therapeutic use Female Humans Proteinuria / complications Proteinuria / etiology Renin-Angiotensin System Canagliflozin Sodium-Glucose Transporter 2 Inhibitors
PMC10237351
37274321
Canagliflozin on top of dual renin-angiotensin system blockade in a woman with partial acquired lipodystrophy, type 2 diabetes and severely proteinuric chronic kidney disease: a case report
2023